3D bioprinting sustained-release microneedle patch used after brain glioma operation and preparation method thereof
The GFD nanozyme composite microneedle patch prepared by 3D bioprinting and combined with hydrogel substrate has solved the problems of tumor recurrence and chemotherapy resistance after glioma surgery, and achieved efficient delivery and precise release of drugs in the brain, thus enhancing the therapeutic effect.
Patent Information
- Application Number
- CN202511362926.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-23
- Publication Date
- 2025-11-04
AI Technical Summary
Postoperative tumor recurrence and chemotherapy resistance following glioma surgery, along with blood-brain barrier drug delivery barriers, make it difficult for current treatment options to effectively kill residual tumor cells and result in insufficient drug concentrations in the brain.
A sustained-release microneedle patch composed of GFD nanozyme and hydrogel substrate was prepared using 3D bioprinting technology. It was designed as a cone-shaped microneedle array and has pH-responsive drug release performance, which can penetrate the pia mater and accurately release drugs in the tumor microenvironment.
This approach achieves complete adhesion between the microneedle patch and the residual cavity wall, precisely controls drug release, improves chemotherapy efficacy, reduces systemic toxicity, and enhances the precision and effectiveness of treatment.
Smart Images

Figure CN120884524A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The application relates to a 3D bioprinted sustained-release microneedle patch for brain glioma postoperative treatment and a preparation method thereof, and belongs to the technical field of new biological medicines. BACKGROUND
[0002] Brain glioma is the most common malignant tumor in the central nervous system, among which glioblastoma (GBM) has the highest malignancy. The existing treatment scheme mainly comprises “maximum surgical resection + postoperative radiotherapy + temozolomide chemotherapy”, but there are two core treatment bottlenecks, which urgently need innovative technology breakthroughs. Postoperative tumor recurrence and chemotherapy resistance dilemma Tumor residue and invasion characteristics: brain glioma has high invasiveness and infiltrative growth characteristics, tumor cells can penetrate into the surrounding normal brain tissue, and the boundary with healthy tissue is blurred, so that the tumor cannot be completely removed by surgery, and the residual tumor cells become the source of recurrence. Under the stimulation of the hypoxic microenvironment, the residual tumor cells can enhance the chemotherapy resistance through the activation of the HIF-1 alpha signaling pathway, reprogramming of iron metabolism and other mechanisms, and further reduce the treatment effect.
[0003] Blood-brain barrier (BBB) drug delivery obstacle: the blood-brain barrier as a natural protective barrier of the central nervous system has high selective permeability characteristics, and most of the chemotherapy drugs (such as doxorubicin, temozolomide, etc.) are difficult to penetrate, resulting in a drug concentration in the tumor site far below the treatment threshold, which cannot effectively kill the residual tumor cells, and limits the clinical efficacy of postoperative chemotherapy.
[0004] Limitations of existing drug delivery technologies Defects of traditional systemic administration: under the systemic administration mode such as intravenous injection, the drug needs to circulate to the brain through the blood, which is easy to be metabolized and eliminated by organs such as liver and kidney, and may also cause systemic toxic side effects. At the same time, due to the obstruction of the blood-brain barrier, the enrichment efficiency of the drug in the brain tumor site is extremely low, which is difficult to meet the treatment needs.
[0005] Deficiency of conventional local drug delivery technology: the existing local drug delivery means (such as surgical implantation of chemotherapy wafers) has problems such as uncontrollable drug release, poor adhesion to the tumor residual cavity, and inability to adapt to irregular residual cavity morphology, which is easy to form a “treatment dead space”. Moreover, most of the carriers do not have responsive release capability, and cannot achieve targeted drug release under the tumor microenvironment (such as acidic pH and high H2O2 level), so that the treatment accuracy and effectiveness are limited. SUMMARY
[0006] In order to solve the above technical problems, the application discloses a 3D bioprinting sustained-release microneedle patch for brain glioma postoperative use, and a specific technical scheme is as follows: the 3D bioprinting sustained-release microneedle patch is made of GFD nanosomes and a hydrogel base material, the GFD nanosomes are gambogic acid-iron-doxorubicin nanosomes, and the hydrogel base material is composed of photocrosslinked gelatin (GelMA), methacrylated hyaluronic acid (HAMA), a photoinitiator and an ultraviolet absorber. The raw materials are as follows in terms of mass fraction: 10 parts of GFD nanosomes, 500 parts of GelMA, 50 parts of HAMA, 25 parts of a photoinitiator and 5 parts of an ultraviolet absorber. The photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (LAP). The ultraviolet absorber is UVAW.
[0007] Preferably, the preparation raw materials of the GFD nanosomes include gambogic acid (GA), iron trichloride hexahydrate (FeCl3·6H2O), doxorubicin hydrochloride (DOX·HCl) and polyvinylpyrrolidone (PVP). The molar ratio of the raw materials is Fe 3 +: GA: DOX = 2:1:1.8, and the addition amount of PVP is 5 times the mass of FeCl3·6H2O.
[0008] Preferably, the structure of the microneedle patch is a conical microneedle array, the single-needle height is 800 μm, the base diameter is 300 μm, the needle tip curvature radius is less than 20 μm, and the array spacing is 1 mm; the microneedle has a porous structure, the pore size is 10-50 μm, and the GFD nanosomes are uniformly distributed in the microneedle.
[0009] Preferably, the microneedle patch has a pH-responsive release performance: in PBS with a pH of 6.5, the 24-hour drug cumulative release rate is greater than or equal to 60%, the 72-hour Fe 2 + cumulative release rate is greater than or equal to 82%, and the 24-hour swelling rate is 182±12%; in PBS with a pH of 7.4, the 24-hour drug cumulative release rate is less than or equal to 30%, the 72-hour Fe 2 + cumulative release rate is less than or equal to 55%, and the 24-hour swelling rate is 145±8%.
[0010] Preferably, the mechanical performance of the microneedle patch meets the following requirements: the single needle can withstand a compression force of greater than or equal to 0.2 N, the soft brain membrane is formed into a microchannel, and there is no obvious inflammatory reaction to the brain tissue after puncture.
[0011] Preferably, the GFD nanoscale enzyme has multiple enzyme activities: under the condition of pH 6.5, the peroxidase-like activity is detected by TMB color development method, the absorbance of 80 μg / mL GFD group at 650 nm is greater than or equal to 1.5; the glutathione peroxidase-like activity is detected by DTNB method, the GSH consumption rate of 30 μg / mL GFD group within 6 hours is greater than or equal to 78%; the catalase-like activity is detected by microplate method, the H2O2 decomposition rate of 50 μg / mL GFD group within 5 minutes is greater than or equal to 65%.
[0012] The application also includes a preparation method of the microneedle patch, comprising the following steps: S1. Preparation of GFD nanoscale enzyme: 20 mg FeCl3·6H2O and 100 mg PVP are dissolved in 10 mL methanol, and stirred for 10 minutes; 10 mg GA and 18 mg DOX·HCl are dissolved in 2 mL methanol respectively, and added dropwise into the above mixture, and ultrasonic for 10 minutes, then stirred at room temperature for 24 hours; after dialysis for 24 hours, centrifuged at 10000 x g for 20 minutes, the precipitate is washed and freeze-dried to obtain GFD nanoscale enzyme dry powder; S2. Configuration of microneedle precursor: weigh 500 mg GelMA, 50 mg HAMA, 25 mg LAP and 5 mg UVAW into a brown centrifuge tube, add 10 mL PBS with pH 7.4, and stir in a 37℃ water bath for 30 minutes until dissolved; add 10 mg / mL GFD nanoscale enzyme dry powder, stir and ultrasonic to remove bubbles, to obtain GFD-hydrogel mixed precursor; S3. 3D bioprinting: design a conical microneedle array model through CAD software, use a projection stereolithography bioprinter, set the light intensity to 10 mW / cm 2 , the exposure time to 18 seconds per layer, and the layer thickness to 50 μm, and layer-by-layer print the GFD-hydrogel mixed precursor; S4. Post-processing and sterilization: place the printed microneedle patch in PBS for 5 minutes to remove the un-solidified hydrogel, and then sterilize by ethylene oxide to obtain a 3D bioprinted sustained-release microneedle patch.
[0013] Beneficial effects: The application utilizes the application potential of existing 3D bioprinting and nanoscale enzyme technology, and the technical advantages of 3D bioprinting, uses the 3D bioprinting technology with high-dimensional manufacturing precision, customizes and designs the microneedle array structure according to the irregular shape of the tumor residual cavity of the patient, realizes complete adhesion with the residual cavity wall, and solves the “dead space effect”; at the same time, the technology can accurately control the shape, size and drug loading capacity of the microneedle, and provides the possibility for personalized treatment. BRIEF DESCRIPTION OF DRAWINGS
[0014] Figure 1 is a schematic diagram of a microneedle conical array structure under a scanning electron microscope SEM, Figure 2 is a schematic diagram of the porous structure inside the microneedle under a scanning electron microscope (SEM), Figure 3 is a speed-of-release fold line graph of the drug-loaded microneedle of the application in an acidic environment. DETAILED DESCRIPTION
[0015] The application will be further clarified by the following examples, which should not be construed as limiting the scope of the application. After reading the application, those skilled in the art will be able to modify the application in various ways, and these modifications fall within the scope of the claims appended hereto.
[0016] The application relates to a 3D bioprinted sustained-release microneedle patch for brain glioma postoperative use, which is prepared by compounding GFD nanosomes and a hydrogel base material. The GFD nanosomes are gambogic acid-iron-doxorubicin nanosomes, and the hydrogel base material is composed of photocrosslinked gelatin (GelMA), methacrylated hyaluronic acid (HAMA), a photoinitiator and a UV absorber. The raw materials are as follows in terms of mass fraction: 10 parts of GFD nanosomes, 500 parts of GelMA, 50 parts of HAMA, 25 parts of a photoinitiator and 5 parts of a UV absorber. The photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (LAP), and the UV absorber is UVAW. The preparation raw materials of the GFD nanosomes include gambogic acid (GA), iron trichloride hexahydrate (FeCl3.6H2O), doxorubicin hydrochloride (DOX.HCl) and polyvinylpyrrolidone (PVP), and the molar ratio of the raw materials is Fe 3 +: GA: DOX = 2:1:1.8, and the addition amount of PVP is 5 times the mass of FeCl3.6H2O.
[0017] The structure of the microneedle patch is a conical microneedle array, the height of a single needle is 800 mu m, the base diameter is 300 mu m, the needle tip curvature radius is less than 20 mu m, and the array spacing is 1 mm. The microneedle has a porous structure inside, the pore size is 10-50 mu m, and the GFD nanosomes are uniformly distributed in the microneedle.
[0018] The microneedle patch has pH-responsive release performance: in PBS with a pH of 6.5, the 24-hour drug cumulative release rate is greater than or equal to 60%, the 72-hour Fe 2 + cumulative release rate is greater than or equal to 82%, and the 24-hour swelling rate is 182+12%; in PBS with a pH of 7.4, the 24-hour drug cumulative release rate is less than or equal to 30%, the 72-hour Fe 2 + cumulative release rate is less than or equal to 55%, and the 24-hour swelling rate is 145+8%.
[0019] The mechanical performance of the microneedle patch meets the following requirements: a single needle can withstand a compression force of ≥0.2 N, penetrates the soft meninges to form a microchannel, and has no obvious inflammatory reaction to the brain tissue after puncture.
[0020] The GFD nanozyme has multiple enzyme activities: at pH 6.5, the peroxidase-like activity is detected by TMB color development method, the absorbance of the 80 μg / mL GFD group at 650 nm is ≥1.5; the glutathione peroxidase-like activity is detected by DTNB method, the GSH consumption rate of the 30 μg / mL GFD group within 6 hours is ≥78%; the catalase-like activity is detected by microplate method, the H2O2 decomposition rate of the 50 μg / mL GFD group within 5 minutes is ≥65%.
[0021] Embodiment Preparation of GFD nanozyme (gambogic acid-iron-doxorubicin nanozyme) Reagent preparation: gambogic acid (GA, purity ≥98%), iron trichloride hexahydrate (FeCl3·6H2O), doxorubicin hydrochloride (DOX·HCl), and polyvinylpyrrolidone (PVP, molecular weight 10000) were selected as raw materials, and methanol was used as solvent. All reagents were sterilized; Mixed reaction system construction: 20 mg of FeCl3·6H2O and 100 mg of PVP were added to 10 mL of methanol at room temperature (25±2℃), and magnetic stirring (speed 300 rpm) was performed for 10 minutes until complete dissolution, forming an iron ion-polymer mixture; Drug addition and self-assembly: 10 mg of GA and 18 mg of DOX·HCl were dissolved in 2 mL of methanol to prepare GA methanol solution and DOX methanol solution, respectively; then the two drug solutions were added dropwise to the above iron ion-polymer mixture at a rate of 1 mL / min, and stirring was performed simultaneously; Ultrasonic and incubation treatment: the mixed system was placed in an ultrasonic instrument (power 300 W, frequency 40 kHz) for ultrasonic treatment for 10 minutes to make the system uniformly dispersed; then it was transferred to a light-proof reaction bottle and magnetically stirred (speed 200 rpm) at room temperature for 24 hours to complete the self-assembly reaction; Purification and drying: the suspension after reaction was transferred to a dialysis bag with a molecular weight cutoff of 3500 Da, and methanol was used as the dialysis medium. Dialysis was performed at room temperature for 24 hours (dialysis fluid was replaced every 6 hours), and unreacted small molecular impurities were removed. After dialysis, the suspension was centrifuged at 10000×g for 20 minutes, and the precipitate was collected. The precipitate was washed with ethanol and ultrapure water for 3 times, and finally placed in a freeze dryer (temperature -50℃, vacuum degree 10 Pa) for freeze-drying for 24 hours to obtain GFD nanozyme dry powder, which was sealed and stored in the dark for standby.
[0022] Configuration of microneedle precursor (hydrogel system) Determination of raw material ratio: light cross-linked gelatin (GelMA, degree of substitution 90%), methacrylated hyaluronic acid (HAMA, degree of substitution 80%) as base material, 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (LAP) as photoinitiator, ultraviolet absorber (UVAW) as stabilizer, phosphate buffer solution (PBS, pH 7.4) prepared with ultrapure water as solvent; Dissolution of base material: in a sterile operation table, accurately weigh 500 mg of GelMA, 50 mg of HAMA, 25 mg of LAP, and 5 mg of UVAW with an electronic balance, and place them in a 15 mL brown centrifuge tube (to prevent premature activation of the photoinitiator); Mixing and dissolution: add 10 mL of PBS to the centrifuge tube drop by drop with a pipette, and gently shake to disperse the powder; then place the centrifuge tube in a 37°C constant temperature water bath, and incubate and stir (speed 150 rpm) for 30 minutes, until all the raw materials are completely dissolved, forming a uniform transparent hydrogel precursor; GFD loading: add the GFD nanenzyme dry powder prepared above to the hydrogel precursor at a concentration of 10 mg / mL, and stir with a magnetic stirrer (speed 200 rpm) for 15 minutes, while using ultrasonic treatment (power 200 W, time 5 minutes) to remove bubbles, obtaining a uniform GFD-hydrogel mixed precursor for standby.
[0023] Molding and post-processing of 3D bioprinted microneedle patches Microneedle model design: use CAD software (such as SolidWorks) to design a conical microneedle array model, with parameters set as: single needle height 800 μm, base diameter 300 μm, needle tip curvature radius < 20 μm, array spacing 1 mm; adjust the overall shape of the microneedle array according to the three-dimensional data of the patient's tumor residual cavity obtained by preoperative MRI scanning, to ensure complete adhesion with the residual cavity wall; 3D bioprinter parameter adjustment: use a projection stereolithography bioprinter (model BP8601 Pro), and set the printing parameters as: light intensity 10 mW / cm 2 , exposure time 18 seconds per layer, layer thickness 50 μm, printing platform temperature 37°C; inject the GFD-hydrogel mixed precursor into the printer cartridge, and avoid light for 10 minutes; remove the bubbles in the cartridge; Layered printing: start the printer, according to the designed microneedle model, adopt the layered photocuring method for printing: the printer irradiates the precursor layer by layer through ultraviolet light (wavelength 365 nm), and the GelMA / HAMA is cross-linked and solidified under the action of LAP to form a solid microneedle structure; after printing is completed, the microneedle patch is taken off from the printing platform; Post-processing and sterilization: place the removed microneedle patch in PBS, ultrasonic treatment (power 150W, time 5 minutes), remove the surface uncured hydrogel; then transfer the microneedle patch to a sterile culture dish, use ethylene oxide sterilization (temperature 30℃, sterilization time 6 hours), after sterilization, place it in a sterile environment and cool to room temperature, ready for use.
[0024] 2.4 Performance characterization and verification of microneedle patch (to ensure product effectiveness and safety) Morphology and structure characterization: use scanning electron microscope (SEM, acceleration voltage 5kV) to observe the surface morphology of microneedle, such as Figure 1 , needle tip sharpness and internal porous structure (pore size 10-50μm), such as Figure 2 , observe the uniformity of fluorescently labeled GFD distribution in microneedle by laser confocal microscope (CLSM); Mechanical property test: use universal material testing machine to test the compression of microneedle at a rate of 0.5mm / min, record the single needle breaking force (≥0.2N to ensure that it can penetrate the soft brain membrane); use PDMS film to simulate brain tissue, test the puncture threshold force of microneedle to verify its penetration ability; Swelling and release performance test: immerse the microneedle patch in PBS with pH6.5 (simulate tumor microenvironment, such as Figure 3 ) and pH7.4 (simulate normal tissue environment) respectively, 37℃ constant temperature oscillation (speed 150rpm), take samples at preset time points (0, 4, 8, 12, 24, 48, 72 hours), use ultraviolet spectrophotometry (GA detection wavelength 360nm, DOX detection wavelength 480nm) to determine the drug release amount, calculate the cumulative release rate; at the same time, measure the 24 hour swelling rate (swelling rate under pH6.5 condition should be ≥180%, under pH7.4 condition should be ≥145%); Enzyme activity verification: use TMB / OPD colorimetric method to detect the peroxidase-like activity of GFD released by microneedle, DTNB method to detect glutathione peroxidase-like activity, microplate method to detect catalase-like activity, to ensure that its multi-enzyme activity meets the design requirements (such as under pH6.5 condition, H2O2 decomposition rate ≥65% / 5 minutes).
[0025] It will be obvious to a person skilled in the art that the application is not limited to the details of the foregoing exemplary embodiments and can be implemented in other concrete forms without departing from the spirit or essential characteristics of the application. The embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the application being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. No reference signs in the claims should be considered as limiting the scope of the claims to the identity of the reference signs therein.
[0026] Furthermore, it should be understood that although the description is made on the basis of the embodiments, not every embodiment contains only one independent technical solution, and the description of the specification is only for the sake of clarity, and those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that those skilled in the art can understand.
Claims
1. A 3D bioprinted sustained-release microneedle patch for use after glioma surgery, characterized in that, The microneedle patch is made of GFD nanozyme and hydrogel substrate. The GFD nanozyme is gambogeylic acid-iron-doxacin nanozyme. The hydrogel substrate is composed of photocrosslinked gelatin (GelMA), methacrylated hyaluronic acid (HAMA), photoinitiator and ultraviolet absorber. The above raw materials, by weight parts, are as follows: GFD nanozyme 10 parts, GelMA 500 parts, HAMA 50 parts, photoinitiator 25 parts, and UV absorber 5 parts. The photoinitiator is 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (LAP). The ultraviolet absorber is UVAW.
2. The microneedle patch according to claim 1, characterized in that, The raw materials for preparing the GFD nanozyme include gambogeylic acid (GA), ferric chloride hexahydrate (FeCl3·6H2O), doxorubicin hydrochloride (DOX·HCl), and polyvinylpyrrolidone (PVP). The molar ratio of the above raw materials is Fe 3 +:GA:DOX = 2:1:1.8, and the amount of PVP added is 5 times the mass of FeCl3·6H2O.
3. The microneedle patch according to claim 2, characterized in that, The structure of the microneedle patch is a conical microneedle array with a single needle height of 800 μm, a base diameter of 300 μm, a needle tip curvature radius of <20 μm, and an array spacing of 1 mm. The microneedles have a porous structure with a pore size of 10-50 μm, and GFD nanozymes are uniformly distributed within the microneedles.
4. The microneedle patch according to claim 3, characterized in that, The microneedle patch exhibits pH-responsive release properties: in PBS at pH 6.5, the cumulative drug release rate is ≥60% after 24 hours, and the Fe... 2 + Cumulative release rate ≥82%, 24-hour swelling rate 182±12%; in PBS at pH 7.4, 24-hour cumulative drug release rate ≤30%, 72-hour Fe 2 +Cumulative release rate ≤55%, 24-hour swelling rate 145±8%.
5. The microneedle patch according to claim 4, characterized in that, The mechanical properties of the microneedle patch meet the following requirements: a single needle can withstand a compressive force of ≥0.2N, penetrate the pia mater to form a microchannel, and cause no significant inflammatory response to brain tissue damage after puncture.
6. The microneedle patch according to claim 5, characterized in that, The GFD nanozyme exhibits multi-enzyme activity: at pH 6.5, peroxidase-like activity, detected by the TMB colorimetric method, showed an absorbance ≥1.5 at 650 nm for the 80 μg / mL GFD group; glutathione peroxidase-like activity, detected by the DTNB method, showed a GSH consumption rate ≥78% within 6 hours for the 30 μg / mL GFD group; and catalase-like activity, detected by the microplate method, showed an H2O2 decomposition rate ≥65% within 5 minutes for the 50 μg / mL GFD group.
7. A method for preparing a 3D bioprinted sustained-release microneedle patch for postoperative use in glioma surgery as described in any one of claims 1-6, characterized in that, Includes the following steps: S1. Preparation of GFD nanozyme: 20 mg FeCl3·6H2O and 100 mg PVP were dissolved in 10 mL methanol and stirred for 10 minutes; 10 mg GA and 18 mg DOX·HCl were dissolved in 2 mL methanol respectively, and added dropwise to the above mixture. After sonication for 10 minutes, the mixture was stirred at room temperature for 24 hours; after dialyzing for 24 hours, the mixture was centrifuged at 10000×g for 20 minutes, the precipitate was washed and lyophilized to obtain GFD nanozyme powder; S2. Preparation of microneedle precursor: Weigh 500 mg GelMA, 50 mg HAMA, 25 mg LAP, and 5 mg UVAW into a brown centrifuge tube, add 10 mL of pH 7.4 PBS, and stir in a 37°C water bath for 30 minutes until dissolved; add 10 mg / mL of GFD nanozyme powder, stir and sonicate to remove bubbles to obtain the GFD-hydrogel mixed precursor; S3. 3D Bioprinting: A conical microneedle array model was designed using CAD software, and a projection-type stereolithography bioprinter was used with a light intensity of 10 mW / cm². 2 The exposure time was 18 seconds per layer and the layer thickness was 50 μm. The GFD-hydrogel hybrid precursor was printed in layers. S4. Post-processing and sterilization: The printed microneedle patch was placed in PBS and sonicated for 5 minutes to remove the uncured hydrogel. After sterilization with ethylene oxide, the 3D bioprinted sustained-release microneedle patch was obtained.
Citation Information
Cited By
Intelligent algorithm drug delivery system based on ferroptosis synergistic chemotherapy and preparation method thereof
CN121197030A
